Onconetix, Inc. Common Stock

ONCO XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

1.3M

Short interest (May 15)

0.5%

Net Short (Jun 03 ): -3.7%

Borrow Fee

233.50%

↓ 50.3%

Available Shares

300K

↓ 69.5%

Price Chart

Company Overview

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001782107

Asset Type: CS

Market Data

Market Cap: $1,306,960

Employees: 2

Status: Active

Short Interest

Current Borrow Fee 233.50%

Range: 183.98% - 233.50%

Available Shares 300K

Range: 200K - 300K

Recent Changes

Fee Change: ↓ 10.4%

Available Change: ↓ 28.6%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime